about
Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?The immune escape in melanoma: role of the impaired dendritic cell function.Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition.Avβ3 integrin: Pathogenetic role in osteotropic tumors.Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications.miRNAs in melanoma: a defined role in tumor progression and metastasis.An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation.Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression.Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker.Does cilengitide deserve another chance?Immune system and melanoma biology: a balance between immunosurveillance and immune escape.Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family.A large metastatic intramammary lesion of an occult melanoma.Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma.Effect of Age on Melanoma Risk, Prognosis and Treatment Response.Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma.Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer.Current status and perspectives in immunotherapy for metastatic melanoma.Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma[Novel markers in osteo-oncology: the tartrate resistant acid phosphatase in myeloma bone disease]Electron efficiency measurements with the ATLAS detector using 2012 LHC proton-proton collision data
P50
Q35584599-AB524283-C29F-4FD7-A8C0-194E4671014EQ38250071-8D6C84A1-17B4-4BDF-83A5-737B1B1F0902Q38385150-C28C458F-F540-4175-9A47-CE37948D014CQ38540840-A4ABE2D0-0CB1-466B-A24C-0CE2954A702FQ38593774-BBAEBBE9-AF17-408D-8301-B94CFC0740EDQ38617229-49A80E18-047E-459A-AD32-709EB00FB13BQ38980447-D4CAE0A7-7E3C-4FDF-BE9F-CDC9DD515502Q39115441-BEB1F82E-1E18-42C8-A107-137588B5AFAFQ39137073-C54EC09D-4726-426D-A88F-9322018FFDA2Q45026631-9E00A9AB-4DAB-4D6B-8971-E46C1468FBC9Q45752130-D7C7FDDF-15DB-4C5D-AF35-01FAEE25AEC8Q48431517-FB32EC6A-707E-4A3F-B42F-4D076B542442Q49166036-10802BD1-79CD-4B8C-A6E1-6E7E91CFD2B9Q49332955-8EC5C02C-C645-48D9-B6B2-974BD44EA222Q49853034-83F7079E-E6F7-483E-8A3D-960A02272DFBQ51372185-9B73790E-E364-4804-BE40-B77AD870BA3EQ52323778-BB49137A-D49E-450D-A431-9389C0E10A0FQ52726999-8D9A9EB4-6F2C-4AE7-8116-FB4CDDC36FE9Q53073457-B4F67BB6-778D-4896-B530-40C1F4355191Q54574397-38726F35-D4A7-47DA-82DD-340F3628039CQ59403918-F21F7B49-3FAB-49B3-AD0A-0276B9FD02A4Q83933097-1DBE6463-116E-4531-8309-7723EFA120DDQ88233277-2E0F429F-D58C-4894-AEF5-15DDB22C13CC
P50
description
researcher ORCID ID = 0000-0003-2063-1435
@en
wetenschapper
@nl
name
Luigia Stefania Stucci
@ast
Luigia Stefania Stucci
@en
Luigia Stefania Stucci
@es
Luigia Stefania Stucci
@nl
type
label
Luigia Stefania Stucci
@ast
Luigia Stefania Stucci
@en
Luigia Stefania Stucci
@es
Luigia Stefania Stucci
@nl
prefLabel
Luigia Stefania Stucci
@ast
Luigia Stefania Stucci
@en
Luigia Stefania Stucci
@es
Luigia Stefania Stucci
@nl
P106
P1153
36242227100
P21
P31
P496
0000-0003-2063-1435